OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. OncoImmune entered into a license and option agreement in 2016 with Pfizer Inc. regarding ONC-392, a pre-clinical IO program. OncoImmune is based in Rockville, Maryland.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/17 | $15,000,000 | Series A |
3E Bioventures | undisclosed |
